Ordering
Available Variants10 mg
CHA.38517-10mg
Price
€63.12
Available – Dispatch in 14 days
50 mg
CHA.38517-50mg
Price
€212.84
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.38517-10mg | €63.12 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.38517-50mg | €212.84 |
≥95% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C6H10N4 · 4HCl |
|---|---|
| CAS Number | 4506-66-5 |
| Molecular Weight | 284.01 |
| UNSPSC Code | 12352200 |
| EC Number | 224-822-6 |
| NACRES | NA.77 |
| Assay | ≥95% (HPLC) |
| Form | powder |
| Quality level | 100 |
| Storage condition | desiccated |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
FAK Inhibitor 14, also known by its CAS number 4506-66-5, is a potent inhibitor of focal adhesion kinase, an enzyme that plays a crucial role in cellular processes such as migration, proliferation, and survival. This compound has been shown to effectively block the activity of FAK, leading to a decrease in downstream signaling events. As a result, FAK Inhibitor 14 has been investigated as a potential therapeutic agent for the treatment of various cancers, where FAK is often overexpressed. The inhibition of FAK by this compound has been demonstrated to induce apoptosis and inhibit cell growth in cancer cells, highlighting its potential as a novel anticancer therapy. Further research is needed to fully explore the therapeutic potential of FAK Inhibitor 14 and its potential applications in cancer treatment.
